|Bid||349.41 x 900|
|Ask||350.80 x 800|
|Day's range||348.46 - 354.35|
|52-week range||282.21 - 387.42|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||26.31|
|Earnings date||05 Feb 2024 - 09 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||400.00|
With the Nasdaq Composite up by 36% this year, those equities known as the "Magnificent Seven" have done quite a bit of the work. The company in question is biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX).
These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead.
The FDA approved gene-editing therapy Casgevy to treat sickle cell disease. Developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), the one-time treatment harnesses gene editing advancements. Vertex CEO Dr. Reshma Kewalramani says the approach involves extracting a patient's stem cells, correcting the defect in those cells using CRISPR gene editing tools, then re-infusing the edited cells into the patient - relieving painful symptoms. Patients who undergo this $2.2 million procedure may eliminate painful sickle cell crises called VOC's. Kewalramani contrasts the cost against the $4-6 million lifetime price tag for conventional sickle cell management. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.